Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer

BACKGROUND: As with other alkylating agents, cardiac dysfunction can occur with trabectedin therapy for advanced soft tissue sarcomas (STS) or recurrent ovarian cancer (ROC) where treatment options for advanced disease are still limited. Cardiac safety for trabectedin monotherapy (T) for STS or in c...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Autores principales: Jones, Robin L., Herzog, Thomas J., Patel, Shreyaskumar R., von Mehren, Margaret, Schuetze, Scott M., Van Tine, Brian A., Coleman, Robert L., Knoblauch, Roland, Triantos, Spyros, Hu, Peter, Shalaby, Waleed, McGowan, Tracy, Monk, Bradley J., Demetri, George D.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8178483/
https://ncbi.nlm.nih.gov/pubmed/33960681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3903
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares